Cryo-Cell International Files Q3 2024 Amendment
Ticker: CCEL · Form: 10-Q/A · Filed: Oct 17, 2024 · CIK: 862692
| Field | Detail |
|---|---|
| Company | Cryo Cell International Inc (CCEL) |
| Form Type | 10-Q/A |
| Filed Date | Oct 17, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q/A, amendment, financial-reporting
TL;DR
Cryo-Cell filed an amendment for their Q3 2024 results. Check for updates.
AI Summary
Cryo-Cell International, Inc. filed an amendment (10-Q/A) on October 17, 2024, for the quarterly period ended August 31, 2024. The filing provides updated information regarding the company's financial performance and operations for the third quarter of its fiscal year.
Why It Matters
This amendment provides updated financial and operational details for Cryo-Cell International's third quarter, which is crucial for investors to assess the company's current performance and future outlook.
Risk Assessment
Risk Level: low — This filing is an amendment to a standard quarterly report, indicating routine updates rather than significant new risks.
Key Players & Entities
- CRYO CELL INTERNATIONAL, INC. (company) — Registrant
- August 31, 2024 (date) — Quarterly period end date
- October 17, 2024 (date) — Filing date
- 001-40767 (other) — Commission File Number
FAQ
What is the purpose of this 10-Q/A filing?
This filing is an Amendment No. 1 to the Quarterly Report on Form 10-Q for the quarterly period ended August 31, 2024, indicating updates or corrections to the original filing.
What is the period of report for this filing?
The conformed period of report is August 31, 2024.
When was this amendment filed?
This amendment was filed on October 17, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 700 Brooker Creek Blvd, Suite 1800, Oldsmar, FL 34677.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 22-3023093.
Filing Stats: 1,136 words · 5 min read · ~4 pages · Grade level 11.3 · Accepted 2024-10-17 17:13:53
Key Financial Figures
- $0.01 — e on which registered Common Stock, $0.01 par value CCEL NYSE American LLC
Filing Documents
- ccel-20240831.htm (10-Q/A) — 78KB
- ccel-ex31_1.htm (EX-31.1) — 14KB
- ccel-ex31_2.htm (EX-31.2) — 14KB
- ccel-ex31_3.htm (EX-31.3) — 14KB
- ccel-ex32_1.htm (EX-32.1) — 14KB
- 0000950170-24-115377.txt ( ) — 304KB
- ccel-20240831.xsd (EX-101.SCH) — 38KB
- ccel-20240831_htm.xml (XML) — 10KB
Exhibits
Item 6. Exhibits 31.1 Certification of Co-CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Co-CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.3 Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNAT URES In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Cryo-Cell International, Inc. /s/ David Portnoy David Portnoy Co-Chief Executive Officer Cryo-Cell International, Inc. /s/ Mark Portnoy Mark Portnoy Co-Chief Executive Officer Cryo-Cell International, Inc. /s/ Jill M. Taymans Jill M. Taymans Vice President, Finance, Chief Financial Officer Date: October 17,2024 3